DK1487416T3 - Lægemiddelmikropartikler - Google Patents

Lægemiddelmikropartikler

Info

Publication number
DK1487416T3
DK1487416T3 DK03745623.3T DK03745623T DK1487416T3 DK 1487416 T3 DK1487416 T3 DK 1487416T3 DK 03745623 T DK03745623 T DK 03745623T DK 1487416 T3 DK1487416 T3 DK 1487416T3
Authority
DK
Denmark
Prior art keywords
drug microparticles
microparticles
drug
making
methods
Prior art date
Application number
DK03745623.3T
Other languages
English (en)
Inventor
Vered Rosenberger
Anna Drabkin
Itzhak E Lerner
Moshe Flashner-Barak
Naomi Moldavski
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of DK1487416T3 publication Critical patent/DK1487416T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B01J13/06—Making microcapsules or microballoons by phase separation
    • B01J13/12—Making microcapsules or microballoons by phase separation removing solvent from the wall-forming material solution
    • B01J13/125—Making microcapsules or microballoons by phase separation removing solvent from the wall-forming material solution by evaporation of the solvent

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK03745623.3T 2002-03-26 2003-03-25 Lægemiddelmikropartikler DK1487416T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36795702P 2002-03-26 2002-03-26
PCT/US2003/009327 WO2003082247A2 (en) 2002-03-26 2003-03-25 Drug microparticles

Publications (1)

Publication Number Publication Date
DK1487416T3 true DK1487416T3 (da) 2010-03-29

Family

ID=28675427

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03745623.3T DK1487416T3 (da) 2002-03-26 2003-03-25 Lægemiddelmikropartikler

Country Status (16)

Country Link
US (6) US20030224059A1 (da)
EP (5) EP2085072A1 (da)
JP (1) JP2005531521A (da)
KR (1) KR20040098023A (da)
AT (1) ATE450252T1 (da)
AU (2) AU2003226021B2 (da)
CA (1) CA2480377A1 (da)
DE (1) DE60330322D1 (da)
DK (1) DK1487416T3 (da)
EA (1) EA200401252A1 (da)
ES (1) ES2334991T3 (da)
IL (1) IL164152A0 (da)
MX (1) MXPA04009385A (da)
NZ (1) NZ535854A (da)
PT (1) PT1487416E (da)
WO (1) WO2003082247A2 (da)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04009385A (es) 2002-03-26 2005-01-25 Teva Pharma Microparticulas de drogas.
AU2003263480A1 (en) * 2002-09-24 2004-04-19 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of fenofibrate having high bioavailability
JP2006524190A (ja) * 2003-02-20 2006-10-26 テバ ファーマシューティカル インダストリーズ リミティド 薬剤のメントール溶液
EP3087991A1 (en) 2003-11-08 2016-11-02 Prothera Biologics Composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
EP1691795A2 (en) * 2003-12-03 2006-08-23 LifeCycle Pharma A/S Pharmaceutical compositions comprising danazol
US20050202079A1 (en) * 2004-03-15 2005-09-15 Mylan Pharmaceuticals Inc. Novel orally administrable formulation of nitrofurantoin and a method for preparing said formulation
US8216610B2 (en) * 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
US20060141028A1 (en) * 2004-08-13 2006-06-29 Moshe Flashner-Barak Cyclosporin formulations
EP1707197A1 (en) 2005-03-30 2006-10-04 Teva Pharmaceutical Industries Ltd. Formulations containing fenofibrate and a surfactant mixture
WO2006107411A2 (en) * 2005-03-30 2006-10-12 Teva Pharmaceutical Industries Ltd. Formulations containing fenofibrate and surfacant mixture
EA200701750A1 (ru) * 2005-03-30 2008-02-28 Тева Фармасьютикал Индастриес Лтд. Улучшенные составы фенофибрата, содержащие ментол или пэг/полоксамер
US20070148233A1 (en) * 2005-12-28 2007-06-28 Lerner E I Pharmaceutical formulations of fenofibrate having improved bioavailability
US20070015834A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing PEG/Poloxamer
US20070015833A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing menthol
CA2629904C (en) 2005-11-28 2018-07-10 Imaginot Pty Ltd. Oral therapeutic compound delivery system
BRPI0620268B8 (pt) * 2005-12-22 2021-05-25 Oakwood Laboratories LLC composição eficaz como sistema de fornecimento para liberação controlada, seu uso, seu método de fabricação, e método para proteger um agente biologicamente ativo
PT1803441E (pt) 2005-12-28 2009-06-08 Teva Pharma Formulações farmacêuticas de fenofibrato com biodisponibilidade melhorada
BRPI0520821A2 (pt) * 2005-12-28 2009-06-30 Teva Pharma formulações farmacêuticas de fenofibrato com biodisponibilidade melhorada
TW200817047A (en) * 2006-04-03 2008-04-16 Teva Pharma Drug microparticles
EP2134327A1 (en) * 2007-03-13 2009-12-23 Sandoz AG Pharmaceutical compositions of poorly soluble drugs
KR100790954B1 (ko) * 2007-09-13 2008-01-04 영남대학교 산학협력단 이트라코나졸 함유 젤라틴 초미세 미립구
TR201808152T4 (tr) 2008-05-28 2018-07-23 Prothera Biologics Inc Kandan inter-alfa inhibitör proteinlerinin hazırlanması ve bunların bileşimi.
WO2010075065A2 (en) * 2008-12-15 2010-07-01 Banner Pharmacaps, Inc. Methods for enhancing the release and absorption of water insoluble active agents
US8889213B2 (en) 2009-01-26 2014-11-18 Teva Pharmaceutical Industries Ltd. Processes for coating a carrier with microparticles
US20120076838A1 (en) 2009-05-27 2012-03-29 Samyang Biopharmaceuticals Corporation Poorly soluble drug containing microsphere with improved bioavailabilty and method of preparing the same
EP2726512B1 (en) 2011-06-29 2017-10-11 Covidien LP Dissolution of oxidized cellulose
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
IN2014DN09416A (da) 2012-04-25 2015-07-17 Spi Pharma Inc
US9271937B2 (en) 2012-05-31 2016-03-01 Covidien Lp Oxidized cellulose microspheres
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US9499636B2 (en) 2012-06-28 2016-11-22 Covidien Lp Dissolution of oxidized cellulose and particle preparation by cross-linking with multivalent cations
WO2014039987A2 (en) 2012-09-09 2014-03-13 Prothera Biologics, Inc. Treatment of disease using inter-alpha inhibitor proteins
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10413566B2 (en) 2013-03-15 2019-09-17 Covidien Lp Thixotropic oxidized cellulose solutions and medical applications thereof
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
FR3039990B1 (fr) 2015-08-10 2018-07-06 Rhodia Operations Procede d'encapsulation
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
AU2017270580B9 (en) 2016-05-26 2020-01-30 Allergan, Inc. Production of rounded salt particles
WO2018045103A1 (en) * 2016-08-30 2018-03-08 Allergan, Inc. Method of manufacturing coated beads
US20190269765A1 (en) 2016-09-13 2019-09-05 Prothera Biologics, Inc. Methods for treating pulmonary disease using inter-alpha inhibitor proteins
AU2018258466B2 (en) 2017-04-25 2025-05-22 Prothera Biologics, Inc. Methods for quantifying inter-alpha inhibitor proteins
CN112638400A (zh) * 2018-06-25 2021-04-09 泰坦医药品公司 用于释放亲脂性或两亲性药用物质的植入物
WO2021049825A1 (ko) 2019-09-09 2021-03-18 주식회사태준제약 사이클로스포린 및 멘톨 함유 나노 에멀젼 점안 조성물 및 그의 제조 방법
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
WO2022155544A1 (en) 2021-01-15 2022-07-21 Aquestive Therapeutics, Inc. Prodrug compositions and methods of treatment
WO2023015183A1 (en) * 2021-08-02 2023-02-09 Cornell University Polymer nanoparticles via condensed droplet polymerization

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3089818A (en) 1960-06-02 1963-05-14 Baxter Laboratories Inc Water dispersible antibiotics
DE2246013A1 (de) * 1972-09-20 1974-03-28 Boehringer Mannheim Gmbh Verfahren zur herstellung von poroesen tabletten
JPS5429566B2 (da) 1974-09-13 1979-09-25
US4900775A (en) 1988-02-29 1990-02-13 Gaf Chemicals Corporation Solubilization of complexes of water-insoluble organic compounds by aqueous solutions of polyvinylpyrrolidone
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
GB8921710D0 (en) * 1989-09-26 1989-11-08 Mentholatum Co Ltd Ibuprofen triturates and topical compositions containing same
HUT75616A (en) * 1992-03-17 1997-05-28 Pfizer Method for prooucing porous delivery devices
ATE188375T1 (de) * 1992-11-17 2000-01-15 Yoshitomi Pharmaceutical Ein antipsychotikum enthaltende mikrokugel zur verzögerten freisetzung und verfahren für ihre herstellung
IT1264020B (it) * 1993-01-28 1996-09-09 Recordati Chem Pharm Procedimento per la preparazione di microgranuli idonei alla sospensione in liquidi
SI9300504A (en) * 1993-09-28 1995-04-30 Krka Process for preparation solid dispersions and deposits of calcium antagonist dihidropyrimidine derivates and pharmaceutical compositions comprising the same
US5430021A (en) * 1994-03-18 1995-07-04 Pharmavene, Inc. Hydrophobic drug delivery systems
IE75744B1 (en) * 1995-04-03 1997-09-24 Elan Corp Plc Controlled release biodegradable micro- and nanospheres containing cyclosporin
US5766629A (en) * 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
WO1997035584A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Method for treating pain
US6096339A (en) * 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
AU5806998A (en) * 1996-12-31 1998-07-31 Inhale Therapeutic Systems Processes for spray drying solutions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
KR19990001564A (ko) 1997-06-16 1999-01-15 유충식 용해도를 개선한 아졸계 항진균제 및 이를 함유하는 제제
US6027747A (en) 1997-11-11 2000-02-22 Terracol; Didier Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
US20030059471A1 (en) * 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
US6337092B1 (en) * 1998-03-30 2002-01-08 Rtp Pharma Inc. Composition and method of preparing microparticles of water-insoluble substances
US20010038855A1 (en) * 1998-06-05 2001-11-08 Desjardin Michael A. Dosage form for administering prescribed dose
SE9803240D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
DK1313564T3 (da) * 2000-04-26 2010-04-06 Elan Pharma Int Ltd Apparat til hygienisk våd formaling
US6264987B1 (en) * 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US20020001617A1 (en) * 2000-05-26 2002-01-03 Chang-Hyun Lee Rapidly disintegrating tablet and process for the manufacture thereof
US6531158B1 (en) * 2000-08-09 2003-03-11 Impax Laboratories, Inc. Drug delivery system for enhanced bioavailability of hydrophobic active ingredients
WO2002024165A2 (en) 2000-09-20 2002-03-28 Nycomed Pharma As Preparation of vitamin emulsions and concentrates thereof
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
AU2002337692B2 (en) 2001-09-26 2007-09-13 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US6878693B2 (en) * 2001-09-28 2005-04-12 Solubest Ltd. Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
US20030185882A1 (en) * 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
MXPA04009385A (es) 2002-03-26 2005-01-25 Teva Pharma Microparticulas de drogas.
US20020193386A1 (en) * 2002-03-28 2002-12-19 Inigo Pfeiffer Polymorphic form of 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-alpha]pyrimidin-4-one and formulations thereof
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
WO2004075874A1 (en) 2003-02-28 2004-09-10 Anbics Patents-Licences Ag Method for treatment and prevention of acute and chronic pseudomonas aeruginosa airway infections with inhalable macrolides
US20040185108A1 (en) * 2003-03-18 2004-09-23 Short Robert E. Method of preparing gas-filled polymer matrix microparticles useful for delivering drug
US20060068015A1 (en) 2003-10-10 2006-03-30 Per Holm Solid dosage form comprising a fibrate and a statin
DE602004012440T2 (de) 2003-11-21 2009-03-26 Galderma Research & Development Sprühbare zusammensetzung zur verabreichung von vitamin d derivaten

Also Published As

Publication number Publication date
IL164152A0 (en) 2005-12-18
KR20040098023A (ko) 2004-11-18
US9107832B2 (en) 2015-08-18
EP2087882A1 (en) 2009-08-12
US20140134256A1 (en) 2014-05-15
AU2008230007A1 (en) 2008-11-13
ES2334991T3 (es) 2010-03-18
HK1069126A1 (en) 2005-05-13
MXPA04009385A (es) 2005-01-25
US20100092568A1 (en) 2010-04-15
CA2480377A1 (en) 2003-10-09
AU2003226021A1 (en) 2003-10-13
PT1487416E (pt) 2010-01-25
NZ535854A (en) 2006-08-31
US20060141050A1 (en) 2006-06-29
EP1487416A2 (en) 2004-12-22
US20030224059A1 (en) 2003-12-04
ATE450252T1 (de) 2009-12-15
EP2085074A1 (en) 2009-08-05
WO2003082247A3 (en) 2004-02-05
AU2003226021B2 (en) 2008-07-17
EA200401252A1 (ru) 2005-04-28
WO2003082247A2 (en) 2003-10-09
EP2085072A1 (en) 2009-08-05
US20060141051A1 (en) 2006-06-29
US20060141052A1 (en) 2006-06-29
EP1487416B1 (en) 2009-12-02
US8663703B2 (en) 2014-03-04
DE60330322D1 (de) 2010-01-14
EP2085073A1 (en) 2009-08-05
JP2005531521A (ja) 2005-10-20

Similar Documents

Publication Publication Date Title
ATE450252T1 (de) Arzneimittel-mikroteilchen
EA200501586A1 (ru) Фармацевтические продукты
ATE412387T1 (de) Medizinische vorrichtungen
BRPI0514293A (pt) sais de dicetopiperazina, sais de dicetomorfolina ou sais de dicetodioxano para administração de droga
BRPI0413427A (pt) derivados de piridilpirrol ativos como inibidores da cinase
WO2006060547A3 (en) Systems and methods for intra-oral drug delivery
DE602004027936D1 (de) Tocopherolmodifizierte therapeutische arzneimittelverbindung
PL371736A1 (en) Method for administering glp-1 molecules
EE05506B1 (et) Ravimi manustamise vahend eriti progestiinide ja”strogeenide manustamiseks
EA200602137A1 (ru) Гидрогелевые препараты интерферона
DE602005010788D1 (de) Pharmazeutische Zusammensetzungen zur sicheren Verabreichung von bei der Behandlung von Drogenabhängigkeit verwendeten Arzneimitteln
AR032293A1 (es) Estuche farmaceutico
EP1391200A4 (en) DRUG
UY27455A1 (es) Derivados n-(1,4,5,6-tetrahidro-ciclopentapirazol -3-il)- sustituidos. su obtención y uso como fármacos.
AR034213A1 (es) Composiciones de medicamentos sobre la base de agentes anticolinergicos e inhibidores de pde-iv
PY0401585A (es) Formulaciones farmaceuticas liquidas de palonosetron
MXPA05012358A (es) Combinacion farmaceutica que comprende modafinilo y otra droga.
AR034493A1 (es) Combinacion de principios activos para el tratamiento medico de toxicomanias.
ATE262893T1 (de) Darreichungsformen zur behandlung von oralen mykosen
EA200600603A1 (ru) Оральная система доставки лекарственного препарата
MA27418A1 (fr) Ensemble de distribution de medicament.
PL366637A1 (pl) Ukierunkowane dostarczanie leków do leczenia zakażeń pasożytniczych
BR0306843A (pt) Formulações sedativas de não-benzodiazepina
DE602004017164D1 (de) Albuminkonjugate, die eine Glucuron-Verknüpfung enthalten
AU2002332836A1 (en) Stabilizing catheter for protein drug delivery